Prof Dr. TatianaTilli – Oncology and Precision Medicine – Women Researcher Award

Prof Dr. TatianaTilli - Oncology and Precision Medicine - Women Researcher Award

Oswaldo Cruz Foundation - Brazil

AUTHOR PROFILE

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Tatiana Martins Tilli pursued her Doctorate in Medicine from the Instituto Nacional de Câncer (INCA) in Rio De Janeiro, Brazil. Her research focused on the functional characterization of splicing variant isoforms of osteopontin in ovarian and prostate carcinomas. This research was conducted under the guidance of Dr. Etel Rodrigues Pereira Gimba and Dr. Akeila Bellahcène at the Université de Liège during her Sandwich Doctorate. The study highlighted the significance of osteopontin as a molecular marker in ovarian and prostate cancers, emphasizing the role of splicing isoforms.Prior to her doctorate, Dr. Tilli completed her Master's in Medicine at INCA. Her research focused on autoantibodies against osteopontin as potential serum markers in neoplasms. This research further underscored the importance of osteopontin as a molecular marker in oncology and provided insights into its immunological aspects.

PROFESSIONAL ENDEAVORS

After completing her doctorate, Dr. Tilli pursued her postdoctoral research at the University of Alberta in Edmonton, Canada. Her postdoctoral work encompassed areas such as Systems Biology, Cellular Biology, and Molecular Biophysics. This period allowed her to expand her research expertise and collaborate with international experts in her field.Currently, Dr. Tilli serves as a public servant in a full-time and exclusive capacity, dedicating 40 hours weekly as a researcher. Her role involves conducting research in the domain of human health, building on her extensive academic background and professional experience.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Dr. Tilli's research has primarily revolved around osteopontin, a molecule of significant interest in oncology. Her studies have explored the functional characterization of splicing variant isoforms of osteopontin and the potential of autoantibodies against osteopontin as serum markers in neoplasms. These research endeavors have contributed significantly to the understanding of molecular markers in ovarian and prostate cancers.

IMPACT AND INFLUENCE

Dr. Tilli's work has had a substantial impact on the field of oncology, particularly in the identification and characterization of molecular markers in ovarian and prostate cancers. Her research findings have been influential in shaping the current understanding of osteopontin's role in cancer biology and its potential applications in diagnostic and therapeutic strategies.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Tatiana Martins Tilli has established herself as a leading researcher in the field of oncology, with a focus on molecular markers, particularly osteopontin. Her legacy lies in her significant contributions to understanding the role of osteopontin in ovarian and prostate cancers.In the future, Dr. Tilli is expected to continue her groundbreaking research, further exploring the potential applications of osteopontin and its variants in cancer diagnosis, prognosis, and targeted therapy. Her continued dedication to advancing the field of oncology promises to yield further impactful contributions to human health.

NOTABLE PUBLICATIONS

Unlocking Overexpressed Membrane Proteins to Guide Breast Cancer Precision Medicine. 2024

Aptamer-Based Recognition of Breast Tumor Cells: A New Era for Breast Cancer Diagnosis. 2024

Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. 2022

Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. 2021

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. 2021

Dr. Michele Moreau – Oncology Therapeutics and Novel Approaches –  Best Researcher Award

Dr. Michele Moreau - Oncology Therapeutics and Novel Approaches -  Best Researcher Award

Johns Hopkins University - United States

Author Profile

Orcid

EARLY ACADEMIC PURSUITS

Michele Moreau's academic journey began with a Bachelor of Science (B.S.) in Physics from the University of Kentucky in May 2009. Following this foundational degree, Michele pursued a Master of Science (M.S.) in Applied Physics from the Physics Department at the University of Massachusetts Boston, graduating in May 2012. Building upon this, Michele achieved another M.S. in Medical Physics from the Radiological Sciences Department at the University of Massachusetts Lowell in May 2022. These early academic pursuits set the stage for Michele's specialization in the field of biomedical engineering and biotechnology.

PROFESSIONAL ENDEAVORS

During Michele Moreau's academic journey, she served as a Teaching and Research Assistant at the University of Massachusetts Lowell from 2014 to 2023. Her role involved teaching an Introductory Physics Lab course and grading lab reports and quizzes. Furthermore, Michele completed a 6-month internship focused on developing a platform for catalyzing collaborative global Cancer Care Education and Research (CaRE). This initiative aimed to enhance Access to Medical Physics Education and Research Excellence (AMPERE), showcasing her commitment to global health initiatives.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPEUTICS AND NOVEL APPROACHES

Michele Moreau's primary research focus revolves around biomedical research in cancer therapy. As a Graduate Research Trainee from 2015 to 2023 at prestigious institutions such as Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Johns Hopkins School of Medicine, Michele specialized in engineering solid and liquid formulations of smart radiotherapy biomaterials. Her expertise encompasses a wide range of techniques and methodologies, including:Engineering Smart Radiotherapy Biomaterials,Monolayer and 3D Cell Culture etc.,

IMPACT AND INFLUENCE

Michele Moreau's research contributions have the potential to revolutionize cancer therapy by improving the effectiveness of in-situ treatment of tumor masses. Her work on smart radiotherapy biomaterials and associated techniques could significantly enhance the precision and efficiency of cancer treatments, benefiting countless patients worldwide.

ACADEMIC CITES

Michele's research findings and contributions to the field of biomedical engineering and biotechnology have likely been cited in various academic publications, journals, and conferences. Her collaborations with esteemed institutions and her focus on cutting-edge research topics make her a notable figure in the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Michele Moreau is expected to be conferred with a Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts Lowell in August 2023, her legacy in the field is already taking shape. Her multidisciplinary approach to cancer therapy, combining physics, engineering, and biology, paves the way for future advancements in the field. Michele's dedication to improving cancer treatments and her commitment to global health initiatives highlight her potential to leave a lasting impact on biomedical research and patient care.

NOTABLE PUBLICATIONS

Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment. 2024

Pre-Clinical Investigations of the Pharmacodynamics of Immunogenic Smart Radiotherapy Biomaterials (iSRB). 2023

Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination. 2023

Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment. 2023

Phytoradiotherapy to enhance cancer treatment outcomes with cannabidiol, bitter melon juice, and plant hemoglobin. 2023

 

 

Dr. Linxi Zhu – Cancer Genetics – Best Researcher Award

Dr. Linxi Zhu - Cancer Genetics - Best Researcher Award

Nanjing Drum Tower Hospital - China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS:

Linxi Zhu commenced her academic journey at Nanjing University, where she pursued a Bachelor's degree from July 2015 to June 2020. Following her undergraduate studies, she continued her academic pursuit at the same institution, earning a Master's degree from July 2020 to June 2021. Linxi Zhu then advanced further in her educational journey, undertaking a Ph.D. program at Nanjing University from July 2021 to June 2023.

PROFESSIONAL ENDEAVORS:

Since September 2023, Linxi Zhu has been serving as a Surgeon at Nanjing Drum Tower Hospital, marking a significant transition from academic pursuits to practical application in the field of surgery.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS :

Linxi Zhu's research has made notable contributions to the field of cancer genetics. Notably, her work titled "Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression" (published in Cancer Lett., 2024) sheds light on the molecular mechanisms underlying pancreatic cancer progression. Additionally, she has contributed to the development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy, as well as exploring the role of preoperative biliary drainage in postoperative outcomes after pancreaticoduodenectomy.

IMPACT AND INFLUENCE:

Zhu's research impact extends beyond pancreatic cancer, with contributions to the field of intrahepatic cholangiocarcinoma. Her collaborative work on high endothelial venule as a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma (published in Cell Prolif., 2023) underscores her diverse research interests.

ACADEMIC CITES:

Linxi Zhu has published in reputable journals, evident from her publications in Cancer Lett., Clin Chim Acta, Gland Surg, Cell Prolif., and Front Oncol. The citations received for her work demonstrate its scholarly significance and recognition within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS:

Zhu's legacy lies in her comprehensive understanding of pancreatic cancer and related surgical interventions. Her research on individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer showcases innovative approaches. Looking forward, Linxi Zhu is poised to contribute further to the field, leaving a lasting impact on surgical and oncological research.

NOTABLE PUBLICATIONS

Development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy. 2022

Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression. 2024

 

 

 

 

 

Biomedical Advancements in Cancer

Biomedical Advancements in Cancer

 

Introduction: In recent years, the field of biomedical advancements in cancer research has witnessed remarkable breakthroughs that have transformed our understanding of the disease and revolutionized treatment options. These advancements offer new hope to patients and hold the promise of improved outcomes in the fight against cancer.

Subtopics in Biomedical Advancements in Cancer:

Immunotherapy and Immune Checkpoint Inhibitors: Immune checkpoint inhibitors have emerged as a game-changer in cancer treatment, leveraging the body’s immune system to target and eliminate cancer cells. CAR-T cell therapy, PD-1 inhibitors, and CTLA-4 inhibitors are some of the key developments in this area.

Precision Medicine and Genomic Profiling: Advancements in genomic sequencing technologies have paved the way for precision medicine in cancer treatment. Tailoring therapies based on the genetic makeup of a patient’s tumor has improved treatment efficacy and reduced side effects.

Liquid Biopsies for Early Detection: Liquid biopsies involve the non-invasive analysis of blood or other bodily fluids to detect cancer-related genetic mutations and biomarkers. These tests offer early detection capabilities and real-time monitoring of cancer progression.

Targeted Therapies and Personalized Cancer Drugs: Targeted therapies are designed to specifically inhibit the molecular pathways driving cancer growth. Advances in drug development have led to a wide range of targeted treatments, enhancing the effectiveness of cancer therapy while minimizing collateral damage to healthy cells.

AI and Machine Learning in Cancer Diagnosis and Treatment: Artificial intelligence and machine learning algorithms are being employed to analyze vast datasets of medical information, aiding in early cancer diagnosis, treatment planning, and predicting patient outcomes. These technologies have the potential to optimize cancer care and streamline research efforts.

These subtopics represent just a fraction of the exciting developments in the biomedical field related to cancer research. Continued research and innovation in these areas are bringing us closer to more effective treatments, early detection methods, and improved patient outcomes in the battle against cancer.